{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:20:27Z","timestamp":1671297627345},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"45","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.18632\/oncotarget.19750","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T17:07:23Z","timestamp":1501607243000},"page":"78573-78587","source":"Crossref","is-referenced-by-count":5,"title":["Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients"],"prefix":"10.18632","volume":"8","author":[{"given":"Sandra","family":"Irenaeus","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"},{"name":"Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aglaia","family":"Schiza","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"},{"name":"Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Mangsbo","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Wenthe","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Krause","sequence":"additional","affiliation":[{"name":"Department of Radiology, Uppsala University Hospital, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Sundin","sequence":"additional","affiliation":[{"name":"Department of Radiology, Uppsala University Hospital, 751 85, Uppsala, Sweden"},{"name":"Department of Surgical Sciences, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kan","family":"Ahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Radiology, Uppsala University Hospital, 751 85, Uppsala, Sweden"},{"name":"Department of Surgical Sciences, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"T\u00f6tterman","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Loskog","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustav J.","family":"Ullenhag","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85, Uppsala, Sweden"},{"name":"Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ijc.27616","article-title":"International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?","volume":"132","author":"Bray","year":"2013","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8010017","article-title":"Updates in Therapy for Advanced Melanoma","volume":"8","author":"Salama","year":"2016","journal-title":"Cancers (Basel)"},{"key":"3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"Mohr","year":"2017","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Chmielowski","year":"2016","journal-title":"Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Na\u00efve Patients with Metastatic Uveal Melanoma","volume":"10","author":"Rompel","year":"2015","journal-title":"PLoS ONE"},{"key":"6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Ullenhag","year":"2016","journal-title":"Br J Cancer"},{"key":"7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12967-017-1182-z","article-title":"Adenovirus-mediated CD40L gene transfer increases Teffector\/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients","volume":"15","author":"Ullenhag","year":"2017","journal-title":"J Transl Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?","volume":"3","author":"Restifo","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"e61797","DOI":"10.1371\/journal.pone.0061797","article-title":"Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells","volume":"8","author":"Chi","year":"2013","journal-title":"PLoS One"},{"key":"10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.can-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Auh","year":"2011","journal-title":"Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Ryffel","year":"2007","journal-title":"Nat Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Verreck","year":"2006","journal-title":"J Exp Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Raulet","year":"2005","journal-title":"Nature"},{"key":"14","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Hodge","year":"2003","journal-title":"J Immunol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Price","year":"1999","journal-title":"Eur J Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/bjd.14347","article-title":"Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status","volume":"174","author":"Goldinger","year":"2016","journal-title":"British Journal of Dermatology"},{"key":"17","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/ijc.28625","article-title":"Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis","volume":"134","author":"Olszewski","year":"2014","journal-title":"International Journal of Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-10-2917","article-title":"KIT pathway alterations in mucosal melanomas of the vulva and other sites","volume":"17","author":"Ragnarsson-Olding","year":"2011","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cmr.0000130006.46885.a0","article-title":"The RAS-BRAF kinase pathway is not involved in uveal melanoma","volume":"14","author":"de Klein","year":"2004","journal-title":"Melanoma Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/OPTH.S28863","article-title":"Current and emerging treatment options for uveal melanoma","volume":"7","author":"Burnier","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Becher","year":"2015","journal-title":"Cell Death Differ"},{"key":"22","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1158\/1078-0432.ccr-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Wilson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"McBride","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Fu","year":"2009","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"Vogelstein","year":"1998","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:07:00Z","timestamp":1589202420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":25,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["19750","29108250"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19750","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}